Tirzepatide

Details:

Molecular weight: 4813.45 g/mol Compound specification: True Hydrophobic parameter calculation reference value (XLogP3 AA): -6.8 Accurate mass: 4812.5315671 Isotope mass: 4810.5248574 Complexity: 11700 Rotatable chemical bond quantity: 163 Hydrogen bond donor quantity: 58 Hydrogen bond acceptor count: 70 Topical electrode surface area: 1790 Heavy atom quantity: 341 Confirmed atomic stereocenter quantity: 39 Uncertain atomic stereocenter quantity: 0 Uncertain chemical bond stereocenter quantity: 0 Isotope atom count: 0 Covalent bond unit quantity: 1
Tirzepatide is a novel glucagon like peptide-1 receptor (GLP-1) and glucose dependent insulinotropic polypeptide (GIP, also known as gastric inhibitory peptide) dual receptor channel agonist, administered once a week. GLP-1 and GIP both belong to enteropancreatin, which is a peptide secreted by the human gastrointestinal mucosa. The former can bind to receptors on pancreatic islet cells and stimulate insulin secretion, thereby producing hypoglycemic effects. It can also delay gastric emptying and suppress appetite, thereby controlling weight; The latter has functions such as inhibiting gastric acid and pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the action of GLP-1 receptor agonists. Tirzepatide integrates two insulin promoting effects into a single molecule, representing a new class of drugs for the treatment of type 2 diabetes.
Molecular Structure of Tilpotide
This molecule consists of a peptide backbone of 39 amino acids and a side chain at residue Lys20. Among the 39 amino acids, 37 are naturally occurring (or encoded), and two are non naturally occurring non coding amino isobutyric acid residues located at positions 2 and 13. Polypeptides such as tilpotide and semaglutide have similar sequences, and the lys side chain in the sequence is modified with PEG, which is a functional group of the peptide and can increase the water solubility of the sequence. The main physiological function of tilporide is glucose dependent insulin nutritional polypeptide (GIP) and glucagon like peptide-1 (GLP-1) receptor dual agonist, which is being developed for the treatment of type 2 diabetes and has entered the clinical stage.